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Abstract: The subject of our research is the optimization of direct compression (DC), controlled 
release drug matrices comprising chitosan/xanthan gum. The foregoing is considered from two 
main perspectives; the use of low molecular weight chitosan (LCS) with xanthan gum (XG) and the 
determination of important attributes for direct compression of the mixtures of the two polymers. 
Powder flow, deformation behaviour, and work of compression parameters were used to 
characterize powder and tableting properties. Compression pressure and LCS content within the 
matrix were investigated for their influence on the crushing strength of the tablets produced. 
Response surface methodology (RSM) was applied to determine the optimum parameters required 
for DC of the matrices investigated. Results confirm the positive contribution of LCS in enhancing 
powder compressibility and crushing strength of the resultant compacts. Compactibility of the 
XG/LCS mixtures was found to be more sensitive to applied compression pressure than LCS 
content. LCS can be added at concentrations as low as 15% w/w to achieve hard compacts, as 
indicated by the RSM results. The introduction of the plasticity factor, using LCS, to the 
fragmenting material XG was the main reason for the high volume reduction and reduced porosity 
of the polymer mixture. Combinations of XG with other commonly utilized polymers in controlled 
release studies such as glucosamine, hydroxypropyl methylcellulose (HPMC), Na alginate (ALG), 
guar gum, lactose and high molecular weight (HMW) chitosan were also used; all the foregoing 
polymers failed to reduce the matrix porosity beyond a certain compression pressure. Application 
of the LCS/XG mixture, at its optimum composition, for the controlled release of two model drugs 
(metoprolol succinate and dyphylline) was examined. The XG/LCS matrix at 15% w/w LCS content 
was found to control the release of metoprolol succinate and dyphylline. The former preparation 
confirmed the strong influence of compression pressure on changing the drug release profile. The 
latter preparation showed the ability of XG/LCS to extend the drug release at a fixed rate for 12 h of 
dissolution time after which the release became slightly slower. 
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1. Introduction 
Tableting, in pharmaceutical applications, has traditionally been carried out by using direct 
compression (DC) processing due to its simplicity, environmentally friendly (solvent/heat-free) 
nature and time/cost-effectiveness [1]. It is also considered suitable for large-scale, continuous 
production of pharmaceutical products [2]. DC is the preferred tablet preparation method when the 
mixed powders of the active pharmaceutical ingredients (APIs) and excipients are physically 
compressible and stable under high compression forces. In addition, DC processing enhances the 
stability of APIs since no aqueous treatment is needed during formulation [3,4]. Product 
development on a DC platform—including immediate and controlled release tablet 
manufacturing—shows a pronounced reliance on the type of excipients used. 
Hydrophilic polymers have been used in controlled release preparations for the last 50 years [5–
7]. A diverse range of numerous polymers, varying in their origin (natural, semi-synthetic, and 
synthetic) and mechanism of action have been used in sustained release dosage forms. Naturally 
occurring xanthan gum (XG) [8] is a widely used polymer for pharmaceutical applications. XG is a 
hetero, branched, and negatively charged hydrophilic polymer able to swell and/or to form 
hydrogels in aqueous media [9,10]. In this regard, XG has been extensively investigated for 
controlled release drug tablet preparations using either wet granulation or direct compression [11]. 
The former technique is suitable for producing strong compacts, especially because XG in solution is 
well known to be a strong binding agent [12,13]. The later technique is desired in tableting due to the 
advantages it imparts with respect to time and cost. However, XG is associated with a number of 
physical properties that limit its use in DC [14]. For example, it has been found that XG can only 
produce hard compacts when its concentration exceeds 30%–40% w/w within the tablet matrix 
[15,16]. Such a high content of XG has been found to result in undesired/excessive retardation of the 
release of certain drugs [17]. On the other hand, the use of a low XG content (10%–20% w/w) in 
tablets gives rise to low mechanical strength and a tendency to undergo the “burst effect” due to the 
erosion of XG in an acidic environment, thus resulting in faster drug release [18,19]. The apparent 
binding deficiencies between the dry XG granules in addition to their low intrinsic porous structure 
are responsible for the weak, low compressible compacts produced when powders are subjected to 
compression [20]. 
When compression enhancers or drug release modifiers were considered in tablet processing 
for controlled release systems, XG mass content and the strength of compacts used presented the 
two major attributes for optimized drug release. For example, polyethylene glycol (PEG) was found 
to enhance drug release via a zero order profile when a high XG mass content was used. However, 
the crushing strength of such compacts was reduced to values that limit the use of the matrix in DC 
[21]. The same conclusion was deduced when ionic modifiers containing calcium salts e.g., CaHPO4 
were used despite the fact that they produce zero order release [22]. In the same context, XG had to 
be present at a mass content >65% w/w in order to produce readily compressible and compactable 
tablets [23]. 
Addition of polymeric modifiers is the most convenient method used in DC; this is due to the 
high solid-solid binding capabilities they provide at low mass content within the tablet. The 
combination of ethyl-cellulose [24] and hydroxypropyl methyl cellulose [25] with XG showed 
greater drug retardation when used at low content as a copolymer matrix than when XG was used 
alone. Drug release profiles using these matrices followed a zero order kinetic profile attributed to 
the porous structure of these polymers or to polymeric modifiers when a gel layer of XG is formed. 
Furthermore, locust bean gum (LBG) has been added to XG in commercial products (TIMERx®) in 
order to overcome the low compressibility and burst effect of XG in a controlled release matrix that 
displayed zero order kinetics for the release of metoprolol tartrate [26]. However, a high content of 
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LBG was needed (XG:LBG mass ratio of 1:1) in the matrix preparations. Moreover, drug release 
profiles were compared at very similar tablet crushing strengths. This implies that a specific 
controlled release profile is attained at a predetermined matrix porosity. In fact, controlled release 
matrices at different XG:LBG mass ratios attained similar drug release profiles when they all had the 
same crushing strength. However, there was no indication of any relationship between the 
dependence of drug release on tablet porosity when it is changed by varying the compression 
pressure [26]. 
Recently, the use of high molecular weight (HMW) chitosan with XG has been used as an 
effective controlled release system with improved mechanical and flow properties at an XG:chitosan 
mass ratio of 1:1. Unlike most controlled release matrices, the XG:HMW chitosan matrix involved a 
simple preparation method via physical mixing. In addition, the matrix needed no further additives 
i.e., excipients to improve powder flow, compression and compaction properties [27]. Some of these 
features have been attributed to the physical nature of HMW chitosan. For example, it has been 
reported that the increase in crushing strength of compacts made of XG:HMW chitosan is attributed 
to the increase in their porous structure relative to that of compacts made of XG [28,29]. In fact, it is 
the low compressibility of the foregoing that imparts less bridging contacts between surfaces upon 
punch displacement when a compression force is applied. In other words, HMW chitosan acts as a 
porosity enhancing agent. Moreover, compacts composed of XG when used as a single excipient for 
controlled drug delivery are of weak mechanical strength and consequently of faster drug release. 
The foregoing was reported for the controlled drug release of a diclofenac sodium preparation 
containing XG. In this regard, the weak matrix formed accounted for the burst effect during 
dissolution [18]. 
The use of porosity modifiers comprising high HMW chitosan has been given a great deal of 
attention for compression and controlled drug release purposes [27,28,30]. However, as mentioned 
earlier, the content of HMW chitosan was almost equivalent to the amount of XG within the matrix. 
In contrast, the choice of low molecular weight chitosan (LCS) was based on previous evidence on its 
inherent high powder compressibility and compactibility as well as its optimum molecular 
interaction with XG [30,31]. 
However, in most reported studies on controlled release tablets, the main focus of research has 
been on controlling the drug release for a certain time and in a predictable manner, irrespective of 
compression process attributes [30]. Consequently, investigation of the behaviour of powders 
comprising controlled release matrices during processing was not of primary interest. This is clear 
from the fact that the effect of compression parameters was not investigated for optimum tablet 
processing and, concurrently, for controlled drug release profiles when an XG:LCS matrix was used. 
In fact, the %LCS content was found to be a major process attribute in order to attain the desired 
drug release profile. In this context, an LCS content of 15% w/w provided the most suitable ratio for 
interaction with XG [32]. However, there is a lack of information as to why LCS content is crucial for 
enhancing mechanical strength of compacts compared to compression pressure. Ideally a low LCS 
content is most favourable for increased matrix compressibility, though it is not favourable with 
regard to the resultant decrease in the mechanical strength of tablets produced. This decrease is 
attributed to the increased XG content within the XG/LCS matrix [31]. Therefore, compression 
pressure is an important consideration for optimum tabletability of the matrix since it has a 
pronounced influence on the crushing strength of tablets. 
Thus, the core of the current study is to establish an optimum controlled release formulation 
using physical mixtures of tablet matrix components based upon an understanding of powder and 
tableting properties of LCS, XG, and mixtures thereof, during compression. The compression 
pressure, as a key attribute of these properties, was tested for its role in influencing drug release, 
alongside the content of controlled release excipient(s). Optimum tableting parameters have been 
investigated for DC processing of the matrix. Applications of the matrix in controlled release 
preparations were then examined using metoprolol succinate and dyphylline as model drugs. 
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2. Materials and Methods 
2.1. Materials 
LCS (Batch No. GC20140503) with a viscosity of 11 mPa (1% w/v in water), average molecular 
weight of 13 kDa, degree of deacetylation >90% and particle size of ~100 µm (95% of the sample <100 
µm). High molecular weight chitosan with an average molecular weight of 150 kDa, average particle 
size of 180–100 μm, viscosity of 150 mPas (1% w/v in water), and degree of deacetylation of >90% 
(batch No. GC20140510) and D-glucosamine HCl were all obtained from G.T.C. Union Group LTD., 
Qingdao, China. XG was purchased from Jungbunzlauer Ladenburg GmbH, Ladenburg, Germany 
(Batch No. 2504519) having a viscosity range of 1400–1600 mPa (1% w/v in water), average molecular 
weight of 1200 kDa and average particle size less than 180 μm. 
Dyphylline, 7-(2,3-dihydroxy-propyl theophylline), 99%, was obtained from ACROS Organics, 
Geel, Belgium. USP grade metoprolol succinate (MS) was obtained from Ipca Laboratories Ltd., 
Mumbai, India (batch No. A0337986). Hydroxypropyl methylcellulose (HPMC) was purchased from 
Dow Chemical Co., Plaquemine, LA, USA. Sodium alginate and guar gum were obtained from 
Central Drug House, New Delhi, India; α-lactose monohydrate (Pharmatose 200 M) was supplied by 
DFE Pharma, Veghel, the Netherlands. All other reagents used were of analytical grade and were 
accessed from the Jordanian Pharmaceutical Manufacturing Co., (JPM), Naor, Jordan. 
2.2. Experimental Design Using Response Surface Methodology (RSM) 
RSM was used to carry out process optimization by employing two input variables 
representing LCS content and compression pressure and one response variable representing the 
tablet crushing strength. The first input variable was chosen based on previously reported data 
using molecular dynamic simulations, whereby the most favourable complex was formed at an LCS 
content of 15% w/w within an XG/LCS matrix. Tablet crushing strength, not drug release, was 
chosen as the response of the current design. The matrix:drug ratio was fixed at a previously 
reported value of 2.61:1. The foregoing represents the recommended ratio which provides optimum 
drug release performance [32]. Therefore, in order to attain optimum tabletability, the RSM data 
were used to determine the range of compression pressures and/or the LCS content that can 
overcome the low matrix compactibility. 
RSM analysis was carried out using Design-Expert® software version 11; the program Central 
Composite Design was used to build a model employing quadratic parameters for three levels of 
each factor. These levels were lower and upper limits, in addition to middle values, coded as (−1), 
(1), and (0), respectively. The factors considered were compression pressure and LCS content; their 
corresponding codes are listed in Table 1. In the same Table, the star point, or α, representing the 
extreme axial run, was found to have a value of 1.414 for a two factor design according to Equation 
(1) [33]. 
  4/12k=
 
(1) 
where k represents the number of factors. 
These star points are crucial because they represent a methodology to extend beyond the range 
set for the experiment. Limits for this range were set at 20%–60% for LCS content and 69.3–138.7 
MPa for compression pressure. Hence, a new range spreads out in space to span new concentration 
and pressure limits which become 12%–85% LCS (w/w) and 40.6–173.3 MPa, respectively for this 
work (Table 1). The new range is wide enough to specifically include the previously reported LCS 
content of 15% which provided the most favourable interaction with XG [32]. Although 50% w/w 
was the highest chitosan concentration used in previous work for controlled release preparations 
[28,30], the new range extends to an extreme LCS content of 85% w/w (α). The foregoing parameters 
were set to test whether high concentrations of the highly compactible LCS, when mixed with XG, 
are practically necessary in order to obtain tablets displaying a high crushing strength. The design 
space was then tested with a regression function whereby a quadratic equation was used to fit the 
response surface. 
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Table 1. Design of experimental factors and their corresponding codes. Low molecular weight 
chitosan (LCS). 
Codes 
Factor 1 
(LCS Content, % w/w) 
Factor 2 
(Compression Pressure, MPa) 
−α 12 40.6 (117 kg) 
−1 20 69.3 (200 kg) 
0 40 104 (300 kg) 
1 60 138.7 (400 kg) 
+α 85 173.3 (500 kg) 
2.3. Powder Characterization (Micromeritic Properties) 
True, Bulk, and Tapped Densities 
The true density (true) of the powders was recorded using a helium pycnometer 
(Ultrapycnometer 1000, Quantachrome Co., Boynton Beach, FL, USA). The cell volume was first 
calibrated using metal sphere standards. An appropriate amount of sample powder (2–4 ±0.1 g) was 
placed in the instrument and the ρtue (g/cm3) measurements were performed, in triplicate, at a 
temperature of 25 ± 0.5 °C. 
The bulk density (ρbulk) of the samples was determined by weighing and pouring each powder 
into a 100 mL graduated glass cylinder. The volume of unsettled powder was then recorded and 
used to calculate the ρbulk (mass/volume; g/cm3); each sample was measured in triplicate. 
Tapped density was determined by tapping a cylinder (100 mL) containing each powder using 
a tapping device ((SVM, Erweka GmbH, Heusenstamm, Germany) set to 100 taps. This was repeated 
when needed until a constant volume was attained. The new reduced volume (tapped volume) was 
recorded and the ρtap (g/cm3) was then calculated (as per ρbulk) in triplicate for each sample. 
2.4. Scanning Electron Microscopy (SEM) 
The surface morphology of the studied powders and tablets produced was examined using a 
Hitachi SU8030 cold-cathode field emission gun scanning electron microscope (Hitachi High 
Technologies, Tokyo, Japan). Samples were placed on aluminum pin-type stubs after applying an 
appropriate adhesive. Samples were then gold coated to reduce the surface charge using a sputter 
coater (Edwards S150 coater). Coated samples were analyzed under high vacuum at an accelerating 
voltage of 10 kV. Images were previewed and collected at different magnifications using i-scan 2000 
software (Roche Holding AG, Basel, Switzerland). 
2.5. Compact Preparation and Characterization 
Prior to mixing, XG (average particle size of 180 µm) and LCS (particle size <100 µm) powders 
were passed through a sieve with a mesh size of 250 μm and collected on a 90 μm mesh. Thus the 
particle size distribution was effectively narrowed so that LCS and XG of particle size <90 and >250 
µm, respectively were discarded. Consequently, there will be almost no contribution of fine and 
coarse particles with diameters outside the 90–250 µm range. Raw polymers and mixtures at mass 
fractions of LCS of 0, 15, 20, 25, 35, 50, and 100 (w/w %) were weighed and physically mixed in a vial. 
A computer-controlled benchtop single punch tablet press (GTP, Gamlen® Tableting Ltd. 
Nottingham, UK) was utilized to carry out compression experiments. Prepared samples, equivalent 
to 150 mg (±5 mg), were poured into a 6 mm diameter circular die. Compression was carried out 
using circular flat-faced punches at a speed of 60 mm/min. Five different compression forces in the 
range of 100–500 kg, which is equivalent to 34.6–173.2 MPa, were applied to produce compacts. At 
each compression pressure, three tablets were produced from each mixture in order to ensure 
reproducibility. The crushing force and thickness of the tablets produced were measured using a 
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crushing forces tester (Pharma Test PTB 311E. Hainburg, Germany) and a Vernier caliper, 
respectively. The crushing strength was then calculated based on Equation (5) in Table 2. 
 
Table 2. Equations used for the calculation of tableting parameters. 
 
Property Equation * Number 
Powder porosity (
p ) 





−
true
bulk


1
 
(2) 
Compact porosity ( c ) 





−
true
app


1
 
(3) 
Degree of compression (DOC) 100
0
0

−






H
pHH
 
(4) 
Crushing strength (σ) 2F/πDh
 
(5) 
Carr index 100
−








tap
bulktap


 
(6) 
Hausner ratio 





bulk
tap


 
(7) 
* bulk, tap, represent bulk, tapped, and true densities. The apparent density (app) of the compacts was 
calculated from the weight (g) and volume (cm3) of the compacts. The degree of compression (DoC; 
%) gives an indication of the extent of packing of a powder under compression whereby H0 and Hp 
are the height (mm) of the filled powder before and after compression, respectively. For the 
crushing strength (σ, MPa) of the produced compacts; F is crushing force (N), D is tablet diameter 
(m), and h is tablet thickness (m). 
2.6. Compression Analysis 
The flowability of raw powdered polymers and their mixtures, in addition to the powder (εp) 
and compact (εc) porosity, degree of compression (DoC; %) and tablet crushing strength (σ) were 
analyzed using Equations (2–5) given in Table 2. 
The in-die compressibility properties of the powders were determined by means of the Heckel 
and Kawakita parameters [34–37]. The Heckel equation (Equation (8)) is used to correlate the 
porosity reduction of powders during the compaction phase with the applied pressure P (MPa) as 
follows: 
𝐼𝑛 
1
1−𝑝𝑟
= 𝑘𝑃 + 𝐴 (8) 
where ρr is the relative density (ρapp/ρtrue) of the compacts and k is the slope of the linear portion of 
the curve that is used to calculate the yield pressure (Py), the inverse of k. Py (MPa) is a measure of the 
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plasticity of the material. The coefficient A indicates the extent of die filling and rearrangement of 
particles. 
Kawakita analysis (Equation (9)) was used to evaluate compressibility via the degree of volume 
reduction, C, of powders under an applied compression pressure, P (MPa), as follows : 
𝑃
𝐶
=  
𝑃
𝑎
+  
1
𝑎𝑏
 
(9) 
where a is a constant related to the porosity of the material, whereas the constant b relates to the 
plasticity of the material and ab is a constant that indicates the degree of particle rearrangement 
within the die. The reciprocal of b (1/b) represents the pressure required to reduce the bulk volume of 
the powder tested by 50%. 
2.7. Analysis of Compression Output and Energy Consumption 
During the compression process (compaction and ejection), the GTP controller tracks the upper 
punch displacement (mm) in relation to the applied load (kg) and generates load-displacement 
curves. The captured data is used to estimate the work of compression (WoC) and elastic recovery 
(WoE) represented by areas ABD and CBD in Figure 1, respectively. 
 
Figure 1. A representative GTP generated load-displacement curve of a xanthan gum (XG) sample at 
400 kg load. 
2.8. In-Vitro Release of Model Drugs Using the XG/LCS Matrix 
Metoprolol succinate and dyphylline were chosen as two freely water soluble drugs for in vitro 
dissolution studies. The former drug was used to examine the relationship between the crushing 
strength of the tablets and the release of the drug. The latter drug was used to confirm the release 
phenomena at different XG/LCS ratios. 
For metoprolol succinate, the procedure was carried out as follows. Metoprolol succinate (12 g) 
was physically mixed with 48 g of the XG/LCS matrix containing 15% w/w (7.2 g) LCS. The 
preparation was compressed by means of a single punch tablet press (Manesty F3 single stroke tablet 
press; West Pharma services Ltd., Dorset, UK) using a 9 mm circular punch. Tablet weight was 
adjusted to 250 mg. The samples were compressed at forces of 20, 30, 40, and 50 kN. At each 
compression force, 20 tablets were weighed, powdered, and then analyzed for content uniformity 
according to the US Pharmacopeia (USP32-NF27) for metoprolol extended release. The tablets 
displayed a USP compliant average assay of 99.02% (RSD = 1.9%) and an average weight of 250.9 mg 
(RSD = 1.5%). The average thickness of five tablets was measured using a caliper in order to 
determine the compact porosity. Values of crushing force of the tablets (10 tablets) resulting from the 
aforementioned compression forces were recorded using the crushing forces tester. Samples 
compressed at the aforementioned compression pressures displayed crushing forces in the following 
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ranges: 40–80, 80–100, 100–120, and 120–150 N, respectively. These ranges are equivalent to 1.8–3.5, 
3.5–4.4, 4.4–5.3, and 5.3–6.6 MPa, respectively. A USP Apparatus II with 50 rpm was set for the 
dissolution run. 500 mL of 0.1 M HCl was used in the first two hours of dissolution run. Keeping the 
tablets intact at the bottom of each vessel, the medium was discarded and replaced with 500 mL of 
phosphate buffer (pH 6.8). From each vessel, 5 mL of each medium was withdrawn at time intervals 
of 0.5, 1, 2, 4, 6, and 8 h followed by compensation with fresh media. The samples were then filtered 
using a 0.4 µm glass filter. Sample absorbance was measured using a UV spectrophotometer 
(LABINDIA UV/VIS, UV 3000, Maharashtra, India) at a wavelength of 274 nm. For each crushing 
strength range, the dissolution of two tablets was tested. The dissolution experiments were 
conducted in duplicate. 
For dyphylline, formulations containing different mass fractions of LCS (0, 15, 25, 35, 50, and 
100% (w/w)) were physically mixed with 100 mg of the dyphylline in order to produce tablets 
weighing 500 mg each. Samples were directly compressed via an industrial single punch tablet press 
(Manesty F3 single stroke tablet press; West Pharma services Ltd., Dorset, UK) using a 12 mm 
circular die with flat-faced punches. The applied force was in the range of 35–40 kN in order to 
maintain a similar crushing strength between all formulations. At each compression force, 20 tablets 
were weighed, powdered, and then analyzed for content uniformity according to the USP 
Pharmacopeia (USP32-NF27) for dyphylline tablets. The tablets displayed a USP compliance average 
assay of 98.10% (RSD = 1.9%) and an average weight of 501.3 mg (RSD = 1.5%). Dissolution studies 
were carried out using a USP apparatus II. Samples (10 mL) were withdrawn at time intervals of 1, 2, 
4, 6, 8, 12, 16, and 20 h and replaced with fresh media. Sample aliquots were analyzed by UV 
spectrophotometry (LABINDIA UV/VIS, UV 3000, Maharashtra, India) at a wavelength of 273 nm. 
2.9. Measurement of Porosity Versus Applied Pressure for Polymer Mixtures 
We compressed 150 mg of binary mixtures or individual components of XG with 15% w/w of 
either LCS, or sodium alginate (Na ALG), or hydroxypropyl methylcellulose (HPMC) or guar gum 
using the GTP at compression forces of 100–500 kg using the 6 mm die. The porosity of each compact 
was calculated at each compression force using Equation (1). Lactose and glucosamine HCl were 
similarly compressed for comparison purposes. 
2.10. XG/LCS Film Preparation and Characterization 
We suspended 10 g of XG/LCS mixtures at an LCS content of 15% w/w in 500 mL of deionized 
water. The suspensions were spread onto Petri dishes which were kept in a vacuum oven (Vacucell, 
MMM Medcenter GmbH, Planegg, Germany) operating at 70 °C for 6 h. Formed films were crushed 
to form powder, passed over a 250 μm mesh and collected on mesh size of 90 μm. Compression was 
carried out by the same method described in the previous section. Compression properties and 
compact porosity were determined thereafter. 
 
3. Results 
3.1. Powder Characterization (Micromeritic Properties) 
The data in Table 3 shows the micrometric properties of LCS, XG and their mixtures. The 
measured density values showed that XG powder is more dense than LCS. In relation to 
inter-granular porosity, LCS particles are more porous than XG particles. The Carr index (CI) and 
Hausner ratio (HR), Equations (6) and (7), respectively in Table 2 were calculated to evaluate the 
flowability of XG, LCS, and mixtures thereof according to USP 35. LCS particles showed poor flow 
characteristics (HR = 1.41, CI = 29.5) whilst XG particles (HR = 1.13, CI = 11.9) and XG/LCS mixture 
containing 15% (w/w) LCS (HR = 1.18, CI = 15.6) displayed good flowability. 
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Table 3. Micrometric properties of XG, LCS, and their mixturesa. 
Sample ρtrue b ρbulk b ρtapped b Porosity Carr Index Hausner Ratio 
XG 1.52 (0.01) 0.66 (0.00) 0.77 (0.01) 0.56 (0.00) 11.9 (0.31) 1.13 (0.01) 
LCS 1.43 (0.03) 0.37 (0.01) 0.52 (0.00) 0.74 (0.02) 29.5 (1.09) 1.41 (0.02) 
LCS50 1.47 (0.01) 0.48 (0.01) 0.62 (0.01) 0.68 (0.01) 22.5 (1.06) 1.29 (0.03) 
LCS35 1.49 (0.01) 0.52 (0.01) 0.66 (0.00) 0.65 (0.01) 21.2 (0.93) 1.27 (0.02) 
LCS25 1.50 (0.00) 0.56 (0.01) 0.69 (0.01) 0.63 (0.01) 17.5 (1.33) 1.22 (0.02) 
LCS15 1.51 (0.01) 0.61 (0.00) 0.71 (0.01) 0.60 (0.00) 15.6 (0.81) 1.18 (0.00) 
a Numbers in parentheses represent SD from the average values. b Density values are in g/cm3. 
3.2. Morphology 
SEM was utilized to visually assess the morphology and qualitatively determine the particle 
size/shape. The SEM images of XG and LCS, Figure 2, show that the majority of LCS particles were 
smaller than 100 μm and have an average size of ~50 μm whereas the XG samples show a particle 
size distribution between 70 and 120 μm. As anticipated, no differences in particle shape were 
found; both XG and LCS consist of irregular shaped particles with rough surfaces and round shaped 
edges. 
 
Figure 2. SEM images showing (A) XG, and (B) LCS powders at a magnification of 400×. 
3.3. Crushing Strength Analysis 
The crushing strength (σ) values of compacts constituted of XG, LCS, and mixtures thereof 
produced using the GTP were measured to assess the mechanical properties (compactibility) of the 
tablets formed; the results are shown in Table 4. Values of σ were plotted against the LCS content in 
the mixture (Figure 3A) at each compression pressure; σ values were also plotted against the applied 
compression pressure (Figure 3B) at each LCS content. It is suggested that such plots give an 
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indication of the sensitivity of crushing strength towards increasing compression pressure and LCS 
content. Initially, the data in the two figures show that LCS forms tablets with higher σ values than 
XG, double the σ values of XG, which indicates high compactibility. On the other hand, XG exhibits 
low compactibility which results in weak compacts. The aforementioned σ sensitivity was 
demonstrated in illustrations that describe changes in the slopes of the equations in Figure 3A and 
3B towards changing compression pressure (Figure 4A) and LCS content (Figure 4B). In this regard, 
there is a clear deflection in the slope (σ versus %LCS) above compression pressure values of 104 
MPa (Figure 4A). On the other hand, the slope remained constant over all the LCS concentration 
range (Figure 4B). 
 
Figure 3. (A) Crushing strength versus LCS content and (B) crushing strength versus compression 
pressure. 
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Figure 4. (A) Dependence of the change in crushing strength on the compression pressure and (B) 
dependence of the change in crushing strength on the content of LCS in the matrix. 
Table 4. Values of σ (MPa) for XG/LCS mixtures compressed at a pressure range of 34.7–173.3 MPa *. 
Sample 
Pressure (MPa) 
34.7 69.3 104.0 138.7 173.3 
XG 0.32 0.67 1.71 2.62 3.62 
LCS50 0.47 (0.01) 1.37 (0.01) 2.63 (0.06) 3.95 (0.10) 5.69 (0.12) 
LCS35 0.45 (0.06) 1.26 (0.05) 2.48 (0.03) 3.71 (0.08) 5.28 (0.10) 
LCS25 0.44 (0.08) 1.14 (0.04) 2.26 (0.06) 3.59 (0.10) 4.91 (0.12) 
LCS15 0.38 (0.01) 1.06 (0.01) 2.08 (0.08) 3.38 (0.02) 4.48 (0.11) 
LCS 0.86 2.21 3.254 5.28 7.06 
* Numbers in parentheses represent the SD from the average values. 
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3.4. RSM Analysis 
Coded factors, their set limits (lower to upper) and responses are presented in Table 5. 
Table 5. Response surface methodology (RSM) parameters for coded factors and their responses for 
the XG/LCS system. 
 Factor 1 (% w/w) Factor 2 (MPa) R1 (crushing strength, MPa) 
1 1 −1 1.57 
2 1 1 4.31 
3 0 0 2.44 
4 −α 0 2.19 
5 −1 1 3.32 
6 0 0 2.44 
7 0 α 5.26 
8 0 0 2.44 
9 α 0 2.68 
10 0 0 2.44 
11 0 0 2.44 
12 0 −α 0.59 
13 −1 −1 1.03 
The responses were best modelled using a quadratic model with the coefficient values given in 
Table 6. The table also shows the p-values for the ANOVA statistical analysis which clearly indicates 
the significance of the model (<0.0001). The p-values of the %LCS content and compression pressure 
factors are <0.05 which implies that the two variables are statistically significant. Moreover, when 
comparing the p-values of the two variables, it is clear that the %LCS content is less significant than 
the compression pressure. The experimental response (crushing strength) and the three-dimensional 
fitted response surface plot are shown in Figure 5. The plot represents the crushing strength (R1) as a 
function of %LCS (A:A) and compression pressure (B:B). The results indicate that the effect of 
compression pressure on the resulting crushing strength of tablets is higher than the effect of %LCS 
in the matrix. These results are in agreement with results presented in the previous section. 
 
Figure 5. The response surface plot of the experimental crushing strength, R1 (red points) and the 
model predictions as a function of %LCS (A:A) and compression pressure (B:B). 
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Table 6. ANOVA analysis for the crushing strength of XG/LCS as a function of LCS content and 
compression pressure. 
Source/Factors 
R1 
Coefficient Estimate of the Actual Equation p-value 
Model *  <0.0001 Significant 
Intercept 2.44  
A 0.276 0.0154 
B 1.45 <0.0001 
AB 0.112 0.3916 
A2 −0.031 0.7513 
B2 0.212 0.0566 
* Equation: Y = 2.44 + 0.276A + 1.45B + 0.112AB − 0.031A2 + 0.212B2, where Y: R1 (MPa), A: LCS content (% w/w), 
B: compression pressure (MPa). 
3.5. Compression Analysis 
Heckel plots (Figure 6) show that porosity values (εc) of the compacts decrease upon increasing 
pressure for all samples. LCS compacts displayed the lowest εc values. The reduction in the value of 
εc for XG remained constant for the compacts when the compression pressure exceeded a threshold 
of 138 MPa. On the other hand, a considerable reduction in ε for LCS and, to a lower extent, XG/LCS 
compacts was still obtained indicating that LCS is more compressible than XG and, more 
importantly, it can modify the compression behaviour of XG. 
 
 
Figure 6. Heckel plot for XG, LCS, and their mixtures. Error bars represent SD values. 
In order to understand the deformation mechanism of the studied powders, the yield pressure 
(PY) was calculated from the linear portion of the Heckel plot. Since PY is the inverse of the slope (k) 
of the linear portion of the plot and is related to the plastic deformation ability of materials, low PY 
values indicate high plasticity of materials. The results shown in Table 7 suggest that LCS 
deformation is governed mainly by a plastic deformation mechanism. Whereas, XG showed a low 
tendency to plastic deformation which suggests the dominancy of brittle fracture behaviour; 
whereby particles undergo fragmentation under applied pressure. XG/LCS mixtures exhibited PY 
values in the range of those exhibited by the two polymers used, which indicates the occurrence of 
multiple deformation processes. 
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Table 7. Calculated compressibility parameters for XG, LCS, and their mixtures. 
Sample PY (MPa) a 1/b ab 
XG 213.48 (8.4) 0.57 (0.01) 34.42 (1.19) 0.02 
LCS 97.340 (2.9) 0.77 (0.03) 8.910 (0.11) 0.09 
LCS50 125.71 (4.1) 0.67 (0.02) 16.01 (0.06) 0.04 
LCS35 128.22 (3.5) 0.64 (0.01) 17.89 (0.33) 0.03 
LCS25 133.45 (5.7) 0.63 (0.00) 19.11 (0.90) 0.03 
LCS15 137.20 (4.5) 0.60 (0.02) 25.46 (0.04) 0.02 
* Numbers in parentheses represent SD values. 
Kawakita plots for XG and LCS compacts are presented in Figure 7. At the same compression 
pressure values, LCS compacts display a higher degree of volume reduction than XG. This explains 
the more dense tablets with higher σ values resulting from LCS samples and indicates, once more, 
the high compressibility of LCS. In contrast, XG displayed a much lower volume reduction during 
compression. The parameters a, 1/b, and ab are presented in Table 7. Referring to the calculated 
values, LCS exhibits high compressibility and volume reduction, whereas XG exhibited the lowest 
value for the “a” parameter. The extent of plastic deformation of materials can be estimated from the 
Kawakita parameter “1/b”. XG showed the highest ‘1/b’ value exceeding the value of LCS by 
four-fold. This further indicates the brittle/fracture nature of XG particles under pressure. The plastic 
deformation behaviour of mixtures is dependent on the mass fraction of LCS such that “1/b” 
decreases with the fraction of LCS. The foregoing is another manifestation of the predominant 
contribution of LCS in the LCS/XG matrix. ab values (Table 7) indicate the increasing extent of 
particle rearrangement with LCS mass fraction, reaching a maximum when LCS is used alone. 
 
Figure 7. Kawakita plots for XG and LCS. 
Data for the degree of compression (DoC) for the compacts produced are presented in Figure 8. 
The results demonstrate the high compressibility and extent of packing of LCS. However, XG 
showed a low extent of packing; it was almost half the value of LCS at low compaction pressures, 
which remained fairly constant at high pressures (138 and 173 MPa). This correlates well with the 
results from the Heckel plot in which a plateau was reached at compaction pressures ≥138 MPa. 
Mixtures of XG and LCS demonstrate DoC values in the range of the two polymers which kept 
increasing even for mixtures with a low fraction of LCS. 
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Figure 8. Degree of compression for XG, LCS and their mixtures. Error bars represent SD values. 
3.6. Force-Displacement Curve Analysis 
The data presented in Figure 9A and B display the work of compression (WoC) and elastic 
recovery (WoE), respectively, as a function of applied compression pressure. Both parameters were 
calculated from the load-displacement curves. It is evident that the WoC increases with pressure for 
all samples. WoC values increased in the presence of LCS, whilst XG exhibited the lowest WoC. 
High stored energy within the tablets, due to compression, can be recovered as elastic work at the 
decompression stage. Calculated WoE values showed that XG and LCS released almost the same 
levels of energy (Figure 9B). WoE values for XG/LCS mixtures were not plotted, for clarity, since 
their values are very similar to XG and LCS. It is to be noted that LCS stored high energy in the 
compression phase and released a small fraction of it upon decompression. This could explain the 
high crushing strength of LCS compacts. On the other hand, XG compacts displayed lower WoC 
values whereas no significant difference in the WoE between XG and LCS compacts was detected. 
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Figure 9. (A) Work of compression (WoC) and (B) work of elastic recovery (WoE) for XG and LCS. 
Error bars represent SD values. 
3.7. Effect of LCS and Different Excipients on Porosity Reduction of Xanthan Gum 
The choice of LCS was investigated in relation to its contribution to a reduction in porosity 
when a compression pressure is applied to XG powder. The reduction in the porosity of XG was 
found to be independent of the applied compression pressure when the value of the latter starts to 
exceed 138.7 MPa (Figures 10 and 11). Polymers commonly utilized in controlled release studies 
such as glucosamine, HPMC, Na ALG, guar gum, lactose, and high molecular weight (HMW) 
chitosan were added to XG to compare their effect on XG porosity. Glucosamine and lactose were 
also used because the former is a constituent of the structure of the chitosan polymer, whilst lactose 
is widely used as a filler in tablets. When 15% w/w LCS was present with XG, porosity continued to 
decrease with applied pressure even at values higher than 138.7 MPa (Figure 10A). Such a decrease 
is typical of the behaviour of LCS when it is compressed as a single excipient. In fact, this behaviour 
was found to be a unique characteristic of LCS compared to other common excipients. In this regard, 
binary mixtures of XG with either glucosamine, HPMC, Na ALG, guar gum, lactose, or high 
molecular weight (HMW) chitosan displayed a porosity-pressure profile similar to that of XG 
(Figures 10 and 11). In other words, the binary mixtures of XG and the aforementioned excipients, 
except LCS, were found to be incompressible after a specific compression pressure. This property 
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makes the XG/LCS mixture suitable for compression into compacts at different crushing strengths 
and also potentially allows a wide spectrum of APIs to be used at a certain compression force which 
modifies their release behaviour. 
 
Figure 10. Dependence of matrix porosity on its composition and compression pressure for XG/LCS 
(A), XG/glucosamine (B), XG/HPMC (C), and XG/ALG (D). Hydroxypropyl methylcellulose 
(HPMC), Na alginate (ALG). 
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Figure 11. Dependence of matrix porosity on its composition and compression pressure for XG/guar 
gum (A), XG/lactose (B) and XG/high molecular weight (HMW) chitosan (C).  
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In order to detect any percolation behaviour in the relationship between porosity and the 
applied pressure, the difference between calculated powder porosity (εp) and the minimum compact 
porosity value (εc) attained as a function of applied pressure was plotted for the XG/LCS mixture at 
LCS content of 15% w/w (Figure 12). 
 
Figure 12. Porosity versus compression pressure plots for XG/LCS matrix and XG. 
3.8. In-Vitro Release of Metoprolol Succinate and Dyphylline 
The relation between the crushing strength and drug release of tablets comprising 50 mg 
metoprolol succinate as an active pharmaceutical ingredient and 200 mg XG/LCS as the controlled 
release matrix is presented in Figure 13. The four ranges of crushing strength show controlled 
release behaviour within 6 h of dissolution. Drug release at the first two low crushing strength 
ranges (1.8–3.5 MPa and 3.5–4.4 MPa), was greater than that at the higher crushing strength ranges 
used (4.4–5.3 MPa and 5.3–6.6 MPa). In addition, drug release of the first two ranges showed almost 
the same dissolution profile. However, the foregoing presented release profiles with a wider 
difference than that of the two matching high crushing strength ranges. Such observation was clear 
starting from the second hour up to the sixth hour of dissolution. This duration was enough to 
differentiate between compacts having variations in crushing strength. On the other hand, compacts 
porosities were higher for tablets of high crushing strength, as indicated in the legend in Figure 13. 
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Figure 13. Relationship between metoprolol succinate release from XG/LCS matrix and its crushing 
strength and porosity. 
The release mechanism of metoprolol matrix comprising XG/LCS was investigated against a 
reference matrix comprising a dried gel powder (film) of the same composition XG/LCS ratio. The 
aim of such a reference was to highlight the impact of the physical mixture undergoing gelling on 
drug diffusion when compared to an already gelled phase. Results of drug dissolution in the 
aforementioned systems are presented in Figure 14. 
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Figure 14. Profiles for metoprolol succinate using XG/LCS matrix as a physical mixture or as a dried 
gel powder of the same composition (A). Regression analyses, Ln (Mt/M) versus Ln time, for 
metoprolol succinate physical mixture (B) and dried gel matrices (C). (Mt/M is the fraction of drug 
released at time t. 
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Dyphylline was chosen as another model drug to assess the efficiency of the LCS-XG based 
compacts as controlled-release drug carriers. This is due to its free solubility in water (>333 mg/mL) 
and short biological half-life (~2 h) [38]. The in-vitro release profiles for dyphylline from XG, LCS 
and their mixtures are shown in Figure 15. Dyphylline shows immediate release from LCS compacts, 
while its release was hindered when incorporated in XG based matrices. Using both XG and LCS 
causes a prolongation in the API release of up to 6–8 h for the 50% LCS tablet mixture. Reducing the 
mass fraction of LCS results in further drug retardation capability of the tablets. Hence, XG/LCS 
mixtures can be used to modify the release of dyphylline. 
 
Figure 15. In-vitro release profiles for dyphylline from XG/LCS compacts at different mass 
percentages of LCS. Error bars represent SD values. 
4. Discussion 
This work aimed to assess the contribution of LCS on the performance of XG in pharmaceutical 
manufacturing and processing of controlled release solid dosage forms. From a powder flow point 
of view, the good flow properties of XG as indicated by the measured Carr index and Hausner ratios 
(Table 3), compared to LCS, necessitates the use of lower concentrations of LCS whenever a 
combination of the two excipients is desired. Despite similarities in particle size and shape of the two 
excipients, the apparent improvement in powder flow for mixtures of high XG content is attributed 
to the higher bulk density of XG compared to that of LCS (Table 3). Accordingly, the low porosity 
recorded for XG when compared to LCS is obviously a result of the highly dense nature of XG. This 
makes the combinations of these polymers a practical prerequisite to obtain a DC matrix. 
The most effective added value that LCS imparts to the XG/LCS mixture is the remarkable 
increase in the crushing strength of the fragile XG compacts. The extent of such an increase was 
found to be sensitive towards applied compression pressure rather than increasing the LCS content 
in the mixture (Figure 3). This was confirmed by the sudden deflection, from almost a plateau state, 
in the slope of the profile above a compression pressure of 104 MPa whereas the slope remained 
constant at all % content of LCS (Figure 4). In other words, hard compacts can be predominantly 
obtained above specific applied pressure values and upon increasing LCS content. Optimal 
responses using RSM procedure confirmed the low attribute of LCS content in tablets crushing 
strength. To be more specific, the RSM technique indicated the low impact of LCS content to achieve 
hard compacts especially when high compression pressures (>104 MPa) were used. Accordingly, an 
LCS content of 15% (w/w) in the mixture represented an optimum value at the minimum chitosan 
concentration that can produce hard compacts when high compression pressures are used. 
Moreover, the use of LCS at an optimum fractional content of 15% (w/w) supports a previous finding 
on optimum LCS content for interaction between XG and LCS using molecular dynamics 
simulations. The later study confirms that the most favourable complex is formed at an LCS content 
of 15% w/w [32]. On the other hand, the use of LCS at low concentrations within the XG/LCS mixture 
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is advantageous when compared to reported work on high molecular weight chitosan and XG 
mixtures [27,28]. The later mixtures showed optimum controlled release behaviour when high 
chitosan content was used or more specifically at the XG: high molecular weight chitosan mass ratio 
of 1:1. 
Irrespective of the content of LCS, its presence with XG is practically imperative from a powder 
compression perspective. Its main significance in the mixture was found to be attributed to the high 
extent of plastic deformation of LCS as illustrated in Heckel (PY) and Kawakita (1/b) analysis upon 
compression of the powder. The last technique further emphasized the importance of having LCS in 
the mixture to overcome low powder compressibility (a) generally attained by XG. This was evident 
in the high particle rearrangement (ab), high volume reduction (C), and high degree of compression 
(DoC) values of the powders when LCS was included in the mixture. 
Since materials with high compression work values utilize the input energy for deformation, 
accordingly the high compression work displayed by the mixture is attributed to LCS as a highly 
deforming material [39]. Theoretically, the compression work is a product of compression force 
times the magnitude of punch displacement; this implies that the high energy displayed upon 
compression of the mixture is attributed to LCS as a highly compressible material. 
The rigid, low porous structure of XG was further found to lose its compressibility around a 
percolation pressure threshold (i.e., >104 MPa) above which no change in the compact porosity was 
attained. On the other hand, the inclusion of LCS, at low content, i.e., 15% w/w, was found to 
eliminate the pressure-porosity threshold as a further reduction in powder porosity was recorded 
above 104 MPa. Bearing in mind that this value—as discussed earlier—represents the compression 
pressure above which high tablet crushing strength can be obtained, it is suggested that there exists a 
combination of two possible explanations for such hard compacts. The first is due to the 
predominant effect of high compression pressures (>104 MPa) in eliminating the weak ability of XG 
to form hard compacts on its own. The second is related to the unique behaviour of LCS in 
enhancing powder volume reduction and further porosity reduction which are the two main factors 
for improved compressibility of XG (Figure 10A). In fact, continuous reduction in porosity did not 
take place above pressures of 104 MPa when XG was mixed with other additives and copolymers 
such as; controlled release excipients (Na ALG, HPMC, and guar gum), fillers (lactose), the unit 
structure of LCS material, i.e., D-glucosamine HCl, and the high molecular weight chitosan (HMW 
chitosan) (Figures 10 and 11). Results confirm a previous finding on the higher extent of powder 
packing from the initial powder volume for LCS when compared to HMW chitosan [31]. The 
difference in powder packing was suggested to be related to the structural configuration difference, 
from intermingled molecular to open structure, as the MW is decreased. Moreover, it was found that 
differences in helical packing contribute to the transfer from plastic to brittle-fracture nature with the 
high extent of packing of chitosan upon compression when the MW is reduced [31]. Based on the 
foregoing, LCS undergoes a higher reduction in powder porosity than HMC confirming the results 
shown in Figures 10A and 11C, respectively. 
It is believed that changes in XG/LCS compact porosity with compression pressure are directly 
related to tablet crushing strength; the latter was found to be pressure sensitive rather than 
influenced by LCS content. These changes were found to be valid whether around a percolation 
threshold (for XG) or in a decreasing behaviour (for the XG/LCS mixture), both taking place upon 
increasing the compression pressure. In other words, the elimination of porosity percolation 
threshold of XG by the inclusion of LCS did not deter the presence of two different dissolution 
profiles ranges of metoprolol tablets which were found to be dependent on tablet crushing strength. 
The foregoing was recorded above a tablet crushing strength of 4.4 MPa when metoprolol drug 
release remained unchanged irrespective of tablet crushing strength. Below this limit, drug release 
was faster for the two crushing strength ranges (1.8–3.5 MPa) and (3.5–4.4 MPa) of the tablets. The 
existence of these two dissolution profile ranges reflects the sensitivity of compact crushing strength 
to compression pressure values as earlier discussed in relation to the data presented in Figure 4A. 
Such drug release, pressure or crushing strength dependence, excluded the possibility of any 
contribution of porosity percolation threshold behaviour as the values of measured porosity for the 
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tablets were in decreasing order as illustrated in Figures 10–12. In this regard, the LCS/XG tablets 
encountered a continuous decrease in porosity with an increase in tablet crushing strength. This 
further emphasizes the fact that LCS modifies drug release by eliminating the porosity/pressure 
percolation threshold encountered with XG; however, tablet crushing strength played a dominant 
factor in drug release. The latter behaviour provides another opportunity to modify the extent of 
drug release via the adjustment of tablet crushing strength without the need to add release 
modifying excipients. 
The release mechanism of metoprolol succinate through the XG/LCS gel layer follows 
non-Fickian diffusion suggesting anomalous transport of the drug rather than through erosion of the 
matrix [40–42]. Apparently, the calculated n-value of the Korsmeyer-Peppas model at a value of 0.59, 
which lies between values of 0.45 and 0.89, justifies this type of diffusion [42]. Moreover, the 
mechanism of diffusion through a gel phase formed from XG/LCS physical mixture is unexpectedly 
similar to that made up from a dried film of the gelled mixture of n-value = 0.55. Although the latter 
value reflects non Fickian diffusion, it is still lower than that of the physical mixture and 
approaching the value of the Fickian behavior (n = 0.45). This indicates that that the gel structure 
from a dried film participates in partial regulation of drug release presumably via the build-up of a 
highly porous matrix structure. 
On the other hand, drug release is faster in an acidic medium compared to a basic medium. The 
foregoing can be explained on the basis of the dependence of the solubility on pH for metoprolol 
succinate which decreases with increasing pH [43]. Such a decrease is attributed to the chemical 
structure of metoprolol succinate salt, which is made of the metoprolol cation and the dicarboxylate 
anion in a 2:1 ratio [44] with a pKa of 9.67 [45]. In this regard, this compound undergoes protonation 
in the acidic pH range, at the amine moiety, leading to enhanced drug solubility. On the other hand, 
when the pH is increased, the compound becomes less protonated until a free base is formed causing 
a reduction in its solubility [46]. 
Finally, LCS does not provide an extended release effect, which was predominantly presented 
by XG, when their influence was tested on dyphylline. In fact, the presence of LCS at the content of 
15% w/w provides the extended release profile of dyphylline for up to 12 h of dissolution time. The 
release profile of the drug with XG was slower compared to that for the matrix system. Therefore, 
the inclusion of LCS at low content (15% w/w) within the XG/LCS matrix can maintain intact 
compacts without any disintegration while extending drug release profiles above 12 h of dissolution 
time. Thus mixtures of XG/LCS present a unique combination in forming intact matrices that 
modulate extended release of freely soluble drugs by varying compression force. 
Examination of the drug release profiles in acidic and basic media for all the matrices 
comprising dyphylline (Figure 15) show that—similar to metoprolol succinate—the release of the 
drug slows down when the medium changes from an acidic to a basic one. Once again, the chemical 
structure of dyphylline plays the main role in such release behavior. In this regard, the amphoteric 
nature of dyphylline with two pKa values (−1 and 8.5–10) allows protonation of the basic group at 
pH values <2 and >8.5 [45,47,48]. This gives rise to increased drug solubility in the HCl dissolution 
medium (pH 1.0). In contrast, drug solubility encounters a decrease in the phosphate buffer (pH = 
6.8) as its remains deprotonated. 
5. Conclusions 
Results confirmed the contribution of LCS to enhanced powder compressibility and high 
compacts crushing strength. Compactibility of the XG/LCS mixtures was found to be more sensitive 
to applied compression pressure than to LCS content. This allows the mixture to be adaptable to a 
wide range of compression forces due to the ability of LCS to reduce powder porosity when mixed 
with XG. Low LCS content was found to maintain a DC matrix. RSM analysis showed that the 
optimum content of LCS in the LCS/XG matrix was around 15%. Furthermore, the matrix which kept 
its high integrity up to 24 h can be used to control the drug release of different APIs. The reported 
system is achievable by using conventional powder processing techniques with satisfactory powder 
flow behaviour. 
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